Clinical Trials Logo

Healthy Adults clinical trials

View clinical trials related to Healthy Adults.

Filter by:

NCT ID: NCT02574858 Completed - Healthy Adults Clinical Trials

Study of the Safety of QRH-882260 Heptapeptide

QRH-882260
Start date: November 2015
Phase: Phase 1
Study type: Interventional

The purpose of this study is to evaluate the safety of orally administered QRH-882260, a topically administered Cy5-labeled heptapeptide specific for epithelial growth factor receptor (EGFR).

NCT ID: NCT02547688 Withdrawn - Healthy Adults Clinical Trials

Assessment of the Tolerability of Dry Airflow in the Nasal Cavity During Sleep

Start date: January 2015
Phase: N/A
Study type: Interventional

Preliminary data show that high flow nasal air has been shown to reduce promote heat exchange due to evaporation of nasal mucus by the air flow resulting in heat loss. It is unclear whether unidirectional nasal airflow is well tolerated in healthy individuals. The central hypothesis of this proposal is that dry high flow nasal air will be sufficiently tolerated in healthy adults.

NCT ID: NCT02460341 Completed - Healthy Adults Clinical Trials

The Effects of Ondansetron on Brain Function

Start date: August 2015
Phase: Phase 1
Study type: Interventional

This project investigates the effects of a single dose of ondansetron on brain function in healthy adults. The investigators hypothesize that there will be a dose-dependent reduction in activation of the insula and somatosensory brain regions associated with the use of ondansetron.

NCT ID: NCT02427373 Completed - Healthy Adults Clinical Trials

A Parallel Bioavailability Study of Fish Oil-Ethyl Ester Versus Fish Oil-Triglyceride Versus Krill Oil

KOMPARE
Start date: June 2014
Phase: N/A
Study type: Interventional

A multiple-dose, double-blind, randomized, four-week, three-treatment, parallel study in which 66 healthy adult subjects will receive 6 capsules/d, administered as a dose of 1.3 g/d eicosapentaenoic acid (EPA)+docosahexaenoic acid (DHA) in fish oil ethyl ester (EE), or fish oil triglyceride (TG) or krill oil for a total of 4 weeks. The objective of the study is to compare the oral bioavailability of EPA+DHA in total plasma across the three formulations at the end of the 4 week study.

NCT ID: NCT02388347 Completed - Healthy Adults Clinical Trials

A Study to Assess the Safety of MEDI7836 in Healthy Adults.

Start date: March 2015
Phase: Phase 1
Study type: Interventional

To assess the safety of a single ascending dose of MEDI7836 in healthy adult male subjects and healthy adult female subjects of non-childbearing potential.

NCT ID: NCT02290665 Completed - Healthy Adults Clinical Trials

Localized Therapeutics for the Treatment of Gastrointestinal Disorders

Start date: January 30, 2015
Phase: N/A
Study type: Interventional

The purpose of this study is to determine the patient preference for a biocompatible thermosensitive solution-gel versus water or saline (liquid) enema. The thermosensitive solution-gel is comprised of poloxamer, an inactive compound that is designated as GRAS (generally recognized as safe) by FDA. It could subsequently be used as a medium for drug delivery. The poloxamer (gel) is administered to study participants in order to assess preference and proximal distribution.

NCT ID: NCT02194764 Completed - Healthy Adults Clinical Trials

An Adherence Tool to Manage Narcotic -Addicted HIV Patients

Start date: June 2014
Phase: N/A
Study type: Interventional

The purpose of this study is to develop a cost-effective breath-based medication adherence monitoring system that can monitor whether recovering opiate addicts actually take a specific treatment medication called naltrexone.

NCT ID: NCT02145234 Completed - Healthy Adults Clinical Trials

Placebo-Controlled, Single and Multiple Ascending Subcutaneous Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BMS-986089 in Healthy Adult Subjects

Start date: June 30, 2014
Phase: Phase 1
Study type: Interventional

The purpose of this study is to evaluate the safety, tolerability, immunogenicity, pharmacokinetics and pharmacodynamics of single and multiple doses of BMS-986089 in healthy adult subjects.

NCT ID: NCT02113306 Not yet recruiting - Healthy Adults Clinical Trials

Does Transcutaneous Vagal Nerve Stimulation Improves Fear Extinction in Humans

t-VNSext
Start date: July 2014
Phase: N/A
Study type: Interventional

A recent study with rats showed that electrical stimulation of the vagus nerve (VNS) facilitates extinction of fear (Pena, Engineer, & McIntyre, Biological Psychiatry, 2013). The hypothesized mechanism is that VNS both enhances memory consolidation (by increasing noradrenergic neurotransmission) and reduces anxiety (thus: preventing fear responses to the CS which may re-consolidate the fear memory). The effect was only apparent when VNS occurred during exposure of the fear conditioned stimulus (CS), and not when stimulation was given immediately following exposure. These results may have implications for the treatment of anxiety disorders in humans. However, until recently, the only means to investigate the effects of VNS on human fear learning would have required the invasive implantation of vagus nerve stimulators. This has fortunately changed, as a non-invasive transcutaneous VNS device has been approved for use in the E.U. for the treatment of psychological disorders. This study proposes to use a t-VNS to investigate its effects on fear learning and extinction in (healthy) humans. Previous research has only investigated the effects it has on human mood and memory. The results obtained suggest that it reduces negative affect and enhances memory, findings which are consistent with those reported for rats. It is thus reasonable to expect that t-VNS will facilitate the extinction of fear in humans. The present study aims to answer the following research questions: Does t-VNS during extinction training: 1. accelerates extinction curves 2. reduces spontaneous recovery of previously extinguished fear 3. reduce re-acquisition of fear 4. reduce generalization of fear to other stimuli that resemble the CS+? 5. facilitates the generalization of inhibitory learning to stimuli that resemble the CS-?

NCT ID: NCT02044679 Completed - Healthy Adults Clinical Trials

Evaluation of Spot Urine as a Biomarker of Fluid Intake in Real Life Conditions

Start date: October 2013
Phase: N/A
Study type: Interventional

Evaluate urine osmolality as a marker of fluid intake, in healthy subjects displaying a wide range of fluid intake behaviors